CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

NCT04156243 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

B Cell Lymphoma
B Cell Leukemia

Interventions

BIOLOGICAL: CD19 CARvac T cells

Sponsor

iCell Gene Therapeutics

Collaborators

[object Object]
[object Object]
[object Object]